The association between neutrophil-to-lymphocyte ratio and anaphylaxis refractory to epinephrine treatment

Objectives: Anaphylaxis refractory to epinephrine treatment is a potentially fatal condition requiring additional medications. Neutrophil-to lymphocyte ratio (NLR) is commonly used to predict severity in allergic diseases. The aim of this study was to determine the association between NLR and refractory anaphylaxis.

Methods: This was a retrospective, observational study of 126 adult anaphylaxis patients arriving at the emergency department between January 2015 and December 2019. Patients were placed into refractory anaphylaxis, if they required more than two 0.3 mg injections of intramuscular epinephrine for symptom resolution, and non-refractory anaphylaxis groups. NLRs were determined at the time of arrival at the hospital and were compared between groups.

Results: Thirty-two (25.4%) patients were categorized as refractory anaphylaxis cases. NLR was significantly lower in the refractory anaphylaxis than in the non-refractory anaphylaxis group (P < 0.001). In the multivariate logistic regression analysis model, NLR was inversely associated with the occurrence of refractory anaphylaxis (adjusted odds ratio 0.33, 95% confidence interval 0.13-0.81, P = 0.016). The area under the receiver operating characteristic curve of NLR for prediction of refractory anaphylaxis was 0.717 (P < 0.001). The optimal cut-off value of NLR was < 0.68 using the Youden index, with 50.0% sensitivity and 80.9% specificity.

Conclusions: NLR was independently and inversely associated with the occurrence of refractory anaphylaxis among anaphylactic patients. Therefore, NLR has the potential to be used as an easy and inexpensive test to predict refractory anaphylaxis in patients.

Anaphylaxis; Rrefractory anaphylaxis; Neutrophil-to-lymphocyte ratio; White blood cells

[1] Simons FER, Ardusso LRF, Bilò MB, Cardona V, Ebisawa M, El-Gamal YM, et al. International consensus on (ICON) anaphylaxis. World Allergy Organization Journal. 2014; 7: 9.

[2] Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. The Journal of Allergy and Clinical Immunology. 2017; 140: 335-348.

[3] Kemp SF, Lockey RF, Simons FER. Epinephrine: the drug of choice for anaphylaxis. a statement of the World Allergy Organization. Allergy. 2008; 63: 1061-1070.

[4] Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. The Journal of Allergy and Clinical Immunology. 2014; 133: 1075-1083.

[5] Francuzik W, Dölle S, Worm M. Risk factors and treatment of refractory anaphylaxis - a review of case reports. Expert Review of Clinical Immunology. 2018; 14: 307-314.

[6] Francuzik W, Dölle-Bierke S, Knop M, Scherer Hofmeier K, Cichocka-Jarosz E, García BE, et al. Refractory anaphylaxis: data from the european anaphylaxis registry. Frontiers in Immunology. 2019; 10: 2482.

[7] Dogru M, Evcimik MF, Cirik AA. Is neutrophil-lymphocyte ratio associated with the severity of allergic rhinitis in children? European Archives of Oto-Rhino-Laryngology. 2016; 273: 3175-3178.

[8] Jiang Y, Ma W. Assessment of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in atopic dermatitis patients. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2017; 23: 1340-1346.

[9] Mochimaru T, Ueda S, Suzuki Y, Asano K, Fukunaga K. Neutrophil-to-lymphocyte ratio as a novel independent predictor of severe exacerbation in patients with asthma. Annals of Allergy, Asthma & Immunology. 2019; 122: 337-339.e331.

[10] Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report-second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Annals of Emergency Medicine. 2006; 47: 373-380.

[11] Brown SGA. Clinical features and severity grading of anaphylaxis. The Journal of Allergy and Clinical Immunology. 2004; 114: 371-376.

[12] Alqurashi W, Alnaji F, Menon K. Refractory anaphylaxis: further considerations for emergency care providers. Annals of Allergy, Asthma & Immunology. 2016; 116: 265-266.

[13] Jang DH, Nelson LS, Hoffman RS. Methylene blue for distributive shock: a potential new use of an old antidote. Journal of Medical Toxicology. 2013; 9: 242-249.

[14] Rukma P. Glucagon for refractory anaphylaxis. American Journal of Therapeutics. 2019; 26: e755-e756.

[15] Tang R, Xu H, Cao J, Chen S, Sun J, Hu H, et al. Clinical characteristics of inpatients with anaphylaxis in China. BioMed Research International. 2015; 2015: 429534.

[16] Kim S, Kim M, Cho Y. Different clinical features of anaphylaxis according to cause and risk factors for severe reactions. Allergology International. 2018; 67: 96-102.

[17] Yanagawa Y, Sakamoto T, Okada Y. Lymphocytosis without anemia in a patient presenting with anaphylactic shock. The American Journal of Emergency Medicine. 2005; 23: 763-766.

[18] Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms. The Journal of Allergy and Clinical Immunology. 2002; 110: 341-348.

[19] LoVerde D, Iweala OI, Eginli A, Krishnaswamy G. Anaphylaxis. Chest. 2018; 153: 528-543.

[20] Jönsson F, Mancardi DA, Kita Y, Karasuyama H, Iannascoli B, Van Rooijen N, et al. Mouse and human neutrophils induce anaphylaxis. The Journal of Clinical Investigation. 2011; 121: 1484-1496.

[21] Jönsson F, Mancardi DA, Albanesi M, Bruhns P. Neutrophils in local and systemic antibody-dependent inflammatory and anaphylactic reactions. Journal of Leukocyte Biology. 2013; 94: 643-656.

[22] Feuerstein G, Hallenbeck JM. Prostaglandins, leukotrienes, and platelet-activating factor in shock. Annual Review of Pharmacology and Toxicology. 1987; 27: 301-313.

[23] Rosales C, Lowell CA, Schnoor M, Uribe-Querol E. Neutrophils: their role in innate and adaptive immunity 2017. Journal of Immunology Research. 2017; 2017: 9748345.

[24] Francis A, Bosio E, Stone SF, Fatovich DM, Arendts G, Nagree Y, et al. Neutrophil activation during acute human anaphylaxis: analysis of MPO and sCD62L. Clinical and Experimental Allergy. 2017; 47: 361-370.

[25] Mitsuhata H, Shimizu R, Yokoyama MM. Role of nitric oxide in anaphylactic shock. Journal of Clinical Immunology. 1995; 15: 277-283.

[26] Evora PRB, Simon MR. Role of nitric oxide production in anaphylaxis and its relevance for the treatment of anaphylactic hypotension with methylene blue. Annals of Allergy, Asthma & Immunology. 2007; 99: 306-313.

[27] Dubey M, Nagarkoti S, Awasthi D, Singh AK, Chandra T, Kumaravelu J, et al. Nitric oxide-mediated apoptosis of neutrophils through caspase-8 and caspase-3-dependent mechanism. Cell Death & Disease. 2016; 7: e2348.

[28] Korenblat P, Lundie MJ, Dankner RE, Day JH. A retrospective study of epinephrine administration for anaphylaxis: how many doses are needed?Allergy and Asthma Proceedings. 1999; 20: 383-386.

[29] Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. The Journal of Allergy and Clinical Immunology. 2004; 113: 1129-1136.

[30] Sclar DA, Lieberman PL. Anaphylaxis: underdiagnosed, underreported, and undertreated. The American Journal of Medicine. 2014; 127: S1-S5.

[31] Karawajczyk M, Haile S, Grabski M, Larsson A. The HemoCue WBC DIFF system could be used for leucocyte and neutrophil counts but not for full differential counts. Acta Paediatrica. 2017; 106: 974-978.

[32] Majors CE, Pawlowski ME, Burke DC, Tkaczyk TS, Rieber A, Richards-Kortum R. Clinical training and validation of the LeukoScope: a low-cost, point-of-care device to perform white blood cell and neutrophil counts. RSC Advances. 2019; 9: 27324-27333.

[33] Heffler E, Terranova G, Chessari C, Frazzetto V, Crimi C, Fichera S, et al. Point-of-care blood eosinophil count in a severe asthma clinic setting. Annals of Allergy, Asthma & Immunology. 2017; 119: 16-20.